FDA Warning Letters Hit Small OTC, Large Pharma Firms With Same Citations In FY 2019
Inadequate process controls and faulty failure investigations were the top GMP violations found in warning letters sent in FY 2019 to companies large and small.
You may also be interested in...
The good news: 75% of never-before-inspected firms complied with US drug GMP requirements. The bad news: 25% did not.
GMP quality, once Mylan's calling card, is now an ongoing problem, forcing product discontinuations and apologies to customers. Firm's valsartan products have European certificate of suitability suspended as Morgantown, W.Va. facility draws US FDA warning letter.
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.